The aim of our study was to investigate the effect of pan-RAF inhibitors (sorafenib and AZ628) and MEK inhibitor (selumetinib) combination treatment on non-V600 BRAF mutant tumor cell lines with various BRAF activities (Table 1). This evidence concerns the gene RAF1 and neoplasm.